1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib
| Autor: | De Langen, J., Cho, B.C., Piotrowska, Z., Le, X., Goldberg, S.B., Goldman, J.W., Okamoto, I., Hewson, N., Maidment, J., Tang, K.H., Veney, N., Cosaert, J., Lau, J., Dressman, M., Ambrose, H., Riess, J.W., Yu, H.A. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1091-S1092 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|